A new analysis from Jefferies shows that drugs receiving breakthrough designations sail through the regulatory process more quickly, on top of frequently winning approval.
FDA Breakthrough Designations Lead to Priority Reviews, Report Finds Read More »
More generous subsidies for Affordable Care Act plans have helped millions of Americans afford insurance. Chances are becoming slimmer and slimmer that the assistance will survive the year.
Republican antipathy during key Senate hearing darkens outlook for ACA subsidy extension Read More »
The drugmaker’s dominance of the obesity market is fueling predictions that years of growth lie ahead.
Eli Lilly Enters Uncharted Territory as Market Cap Nears $1T Read More »
Cuando hablamos de bienestar familiar, pocas decisiones son tan importantes como elegir un seguro médico para niños, especialmente si confiamos en compañías consolidadas como Generali, que se han convertido en un referente para muchas familias que buscan calidad, rapidez …
Seguro de salud para niños: Beneficios y coberturas esenciales Read More »
The purchase would give Abbott access to cancer screening tests including Cologuard and blood tests for multi-cancer early detection.
Aspen is now also considering the possibility of an initial public offering next year in an effort to bring its cell therapy to the market.
Aspen’s $115M Series C Opens Doors to Late-Stage Development for Parkinson’s Program Read More »
Executives blamed Medicaid cuts, commercial insurance denial rates and declining volumes for the staff reduction.
Providence lays off more workers in Washington, Oregon Read More »
En los últimos años, cada vez más personas describen una sensación persistente de cansancio mental: dificultad para concentrarse, pensamientos lentos, alta distracción y la impresión de no rendir al nivel real que podrían alcanzar. Este fenómen …
The approvals come as a pleasant surprise for Regeneron, analysts say, helping bolster the overall product profile of high-dose Eylea despite outstanding manufacturing concerns.
FDA Hands Regeneron Two Eylea HD Nods in One Day Read More »
The nod brings Bayer face-to-face in the market with Boehringer Ingelheim and AstraZeneca, each of which has its own HER2 blocker for non-small cell lung cancer.
Bayer Wins Accelerated Lung Cancer Approval for Kinase Inhibitor Read More »
